Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of$ 0.86. This compares to a loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -2.33%. A quarter ago, it was expected that this company would post a loss of$ 0.86 per share when it actually produced a loss of $0.82, delivering a surprise of +4.65%.Over the last four quarters, the compan ...